Sana Biotechnology logo

Sana BiotechnologyNASDAQ: SANA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 February 2021

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$836.47 M
-80%vs. 3y high
71%vs. sector
-vs. 3y high
-vs. sector
-71%vs. 3y high
64%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 5 min ago
$3.76-$0.03(-0.79%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

SANA Latest News

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
globenewswire.com04 November 2024 Sentiment: -

Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells

Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
globenewswire.com30 September 2024 Sentiment: POSITIVE

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at September 2024 Investor Conferences
globenewswire.com29 August 2024 Sentiment: POSITIVE

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update.

Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
globenewswire.com26 August 2024 Sentiment: POSITIVE

SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.

Sana Biotechnology: SC291 Moving Forward Beyond Hematological Malignancies
Seeking Alpha05 January 2024 Sentiment: NEUTRAL

Additional results from a Sana Biotechnology, Inc. phase 1 study, using SC291 for the treatment of patients with B-cell lymphomas and leukemias, are expected in 2024. Initial results from phase 1 study, using SC291 for the treatment of patients with autoimmune disorders, expected in 2024. Initial results from phase 1 study, using SC262 for the treatment of patients with r/r B-cell Lymphomas who failed prior anti-CD19 therapies, expected in 2024.

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire03 January 2024 Sentiment: POSITIVE

SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Tuesday, January 9, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology: Hypoimmune Platform Might Stealth Cells
Seeking Alpha09 July 2023 Sentiment: POSITIVE

Results from the phase 1 study using SC291 for the treatment of patients with B-cell lymphomas are expected to be released later in 2023. It is said that the global B-cell lymphoma treatment market could reach $13.14 billion by 2030. The company is testing the use of its hypoimmune platform, which might be capable of providing long-term durable responses, without immunosuppression being needed.

Wall Street Analysts Believe Sana (SANA) Could Rally 83.17%: Here's is How to Trade
Zacks Investment Research03 May 2023 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 83.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Why Shares of Sana Biotechnology Jumped This Week
The Motley Fool14 April 2023 Sentiment: POSITIVE

Sana Biotechnology is developing a cell-editing platform that it hopes will be able to avoid immune-system rejection. The company has no revenue but enough cash to fund operations into 2025, it said.

What type of business is Sana Biotechnology?

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

What sector is Sana Biotechnology in?

Sana Biotechnology is in the Healthcare sector

What industry is Sana Biotechnology in?

Sana Biotechnology is in the Biotechnology industry

What country is Sana Biotechnology from?

Sana Biotechnology is headquartered in United States

When did Sana Biotechnology go public?

Sana Biotechnology initial public offering (IPO) was on 04 February 2021

What is Sana Biotechnology website?

https://www.sana.com

Is Sana Biotechnology in the S&P 500?

No, Sana Biotechnology is not included in the S&P 500 index

Is Sana Biotechnology in the NASDAQ 100?

No, Sana Biotechnology is not included in the NASDAQ 100 index

Is Sana Biotechnology in the Dow Jones?

No, Sana Biotechnology is not included in the Dow Jones index

When was Sana Biotechnology the previous earnings report?

No data

When does Sana Biotechnology earnings report?

The next expected earnings date for Sana Biotechnology is 08 November 2024